Do pathogen exposure and innate immunity cause brain diseases?

Neurological Research

Volumn 27, Issue 7, 2005, Pages 717-725

  Simard, Alain R ^a   Rivest, Serge ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Antigen presenting cells; Cytokines; Gliogenesis; Inflammation; Innate immunity; Macrophages; Toll like receptors

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIGEN PRESENTING CELL; BLOOD BRAIN BARRIER; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; T LYMPHOCYTE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN DISEASES; CENTRAL NERVOUS SYSTEM; HUMANS; IMMUNITY, NATURAL; NERVE DEGENERATION;

EID: 27244438637     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164105X49526     Document Type: Review

References (58)

1. Anderson KV. Toll signaling pathways in the innate immune response. Curr Opin Immunol 2000; 12: 13-19
2. Wright SD. Toll, a new piece in the puzzle of innate immunity. J Exp Med 1999; 189: 605-609
3. Schumann RR, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide binding protein. Science 1990; 249: 1429-1431
4. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-1433
5. Nadeau S, Rivest S. Endotoxemia prevents the cerebral inflammatory wave induced by intraparenchymal lipopolysaccharide injection: Role of glucocorticoids and CD14. J Immunol 2002; 169: 3370-3381
6. Perera PY, Vogel SN, Detore GR, et al. CD14-dependent and CD14-independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol. J Immunol 1997; 158: 4422-4429
7. Triantafilou M, Brandenburg K, Gutsmann T, et al. Innate recognition of bacteria: Engagement of multiple receptors. Crit Rev Immunol 2002; 22: 251-268
8. O'Neill LA. Immunology. After the toll rush. Science 2004; 303: 1481-1482
9. Muzio M, Polentarutti N, Bosisio D, et al. Toll-like receptors: A growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J Leukoc Biol 2000; 67: 450-456
10. Beutler B, Hoebe K, Du X, et al. How we detect microbes and respond to them: The Toll-like receptors and their transducers. J Leukoc Biol 2003; 74: 479-485
11. Kopp E, Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol 2003; 15: 396-401
12. Diebold SS, Kaisho T, Hemmi H, et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303: 1529-1531
13. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303: 1526-9
14. Zhang D, Zhang G, Hayden MS, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004; 303: 1522-1526
15. Muroi M, Ohnishi T, Tanamoto K. Regions of the mouse CD14 molecule required for toll-like receptor 2- and 4-mediated activation of NF-kappa B. J Biol Chem 2002; 277: 42372-42379
16. Kawai T, Adachi O, Ogawa T, et al. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999; 11: 115-122
17. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science 2003; 300: 1524-1525
18. Baeuerle PA. Pro-inflammatory signaling: Last pieces in the NF-kappaB puzzle? Curr Biol 1998; 8: R19-22
19. Delhase M, Hayakawa M, Chen Y, et al. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science 1999; 284: 309-313
20. Baeuerle PA, Baltimore D. NF-kappa B: Ten years after. Cell 1996; 87: 13-20
21. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621-663
22. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem 1999; 274: 27339-27342
23. Horng T, Barton GM, Flavell RA, et al. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002; 420: 329-333
24. Yamamoto M, Sato S, Hemmi H, et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002; 420: 324-329
25. Yamamoto M, Sato S, Mori K, et al. Cutting edge: A novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signal ing. J Immunol 2002; 169: 6668-6672
26. Oshiumi H, Matsumoto M, Funami K, et al. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol 2003; 4: 161-167
27. Fitzgerald KA, McWhirter SM, Faia KL, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003; 4: 491-496
28. Sharma S, tenOever BR, Grandvaux N, et al. Triggering the Interferon antiviral response through an IKK-related pathway. Science 2003; 300: 1148-1151
29. Nguyen MD, Julien JP, Rivest S. Innate immunity: The missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 2002; 3: 216-227
30. Oldfield BJ, Mckinley MJ. Circumventricular organs. In: G P, ed, The rat nervous system, San Diego: Academic Press, 1995: pp. 391-403
31. Zhang J, Rivest S. Is survival possible without arachidonate metabolites in the brain during systemic infection? News Physiol Sci 2003; 18: 137-142
32. Turrin NP, Rivest S. Unraveling the molecular details involved in the intimate control of the immune and neuroendocrine systems: A revised and innovative hypothesis. Exp Bio Med 2004; 229: 996-1006
33. Glezer I, Rivest S. Glucocorticoids: Protectors of the brain during innate immune responses. Neuroscientist 2004; 10: 538-552
34. Tracey KJ, Cerami A. Tumor necrosis factor: A pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45: 491-503
35. Piani D, Spranger M, Frei K, et al. Macrophage-induced cytotoxicity of N-methyl-D-aspartate receptor positive neurons involves excitatory amino acids rather than reactive oxygen intermediates and cytokines. Eur J Immunol 1992; 22: 2429-2436
36. Chao CC, Hu S, Ehrlich L, et al. Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: Involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brain Behav Immun 1995; 9: 355-365
37. Strijbos PJ, Rothwell NJ, Interleukin-1 beta attenuates excitatory amino acid-induced neurodegeneration in vitro: Involvement of nerve growth factor. J Neurosci 1995; 15: 3468-3474
38. Westmoreland SV, Kolson D, Gonzalez-Scarano F. Toxicity of TNF alpha and platelet activating factor for human NT2N neurons: A tissue culture model for human immunodeficiency virus dementia. J Neurovirol 1996; 2: 118-126
39. Mustafa MM, Lebel MH, Ramilo O, et al. Correlation of interleukin-1 beta and cachectin concentrations in cerebrospinal fluid and outcome from bacterial meningitis. J Pediatr 1989; 115: 208-213
40. Mustafa MM, Ramilo O, Olsen KD, et al. Tumor necrosis factor in mediating experimental Haemophilus influenzae type B meningitis. J Clin Invest 1989; 84: 1253-1259
41. Arditi M, Manogue KR, Caplan M, et al. Cerebrospinal fluid cachectin/tumor necrosis factor-alpha and platelet-activating factor concentrations and severity of bacterial meningitis in children. J Infect Dis 1990; 162: 139-147
42. van Deuren M, van der Ven-Jongekrijg J, Vannier E, et al. The pattern of interleukin-1beta (IL-1beta) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections. Blood 1997; 90: 1101-1108
43. Hauser SL, Doolittle TH, Lincoln R, et al. Cytokine accumulations in CSF of multiple sclerosis patients: Frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 1990; 40: 1735-1739
44. Sheng JG, Boop FA, Mrak RE, et al. Increased neuronal beta-amyloid precursor protein expression in human temporal lobe epilepsy. Association with interleukin-1 alpha immunoreactivity. J Neurochem 1994; 63: 1872-1879
45. Mogi M, Harada M, Narabayashi H, et al. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 1996; 211: 13-16
46. Sriram K, Matheson JM, Benkovic SA, et al. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease. Faseb J 2002; 16: 1474-1476
47. Gregersen R, Lambertsen K, Finsen B. Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 2000; 20: 53-65
48. Nadeau S, Rivest S. Glucocorticoids play a fundamental role in protecting the brain during innate immune response. J Neurosci 2003; 23: 5536-5544
49. Stepanichev MY, Zdobnova IM, Yakovlev AA, et al. Effects of tumor necrosis factor-alpha central administration on hippocampal damage in rat induced by amyloid beta-peptide (25-35). J Neurosci Res 2003; 71: 110-120
50. Bruce AJ, Boling W, Kindy MS, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 1996; 2: 788-794
51. Scherbel U, Raghupathi R, Nakamura M, et al. Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc Natl Acad Sci U S A 1999; 96: 8721-8726
52. Probert L, Akassoglou K, Pasparakis M, et al. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci U S A 1995; 92: 11294-11298
53. Fontaine V, Mohand-Said S, Hanoteau N, et al. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: Opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 2002; 22: RC216
54. Diem R, Hobom M, Grotsch P, et al. Interleukin-1 beta protects neurons via the interleukin-1 (IL-1) receptor-mediated Akt pathway and by IL-1 receptor-independent decrease of transmembrane currents in vivo. Mol Cell Neurosci 2003; 22: 487-500
55. Arnett HA, Mason J, Marino M, et al. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001; 4: 1116-1122
56. Laflamme N, Lacroix S, Rivest S. An essential role of interleukin-1 beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. J Neurosci 1999; 19: 10923-10930
57. Simard AR, Rivest S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. Faseb J 2004; 18: 998-1000
58. Simard AR, Rivest S. Role of inflammation in the neurobiology of stem cells. Neuroreport 2004; 15: 2305-2310